Pancreatic Islet Cell Transplant for Treatment of Diabetes

Endocrinology and Metabolism Clinics of North America

Volumn 36, Issue 4, 2007, Pages 999-1013

  Fiorina, Paolo ^a,b,d   Secchi, Antonio ^a,c  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d HARVARD STEM CELL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; CYCLOSPORIN; DACLIZUMAB; INSULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ABDOMINAL PAIN; DIET THERAPY; DOPPLER ECHOGRAPHY; GLYCEMIC CONTROL; GRAFT REJECTION; HEMATOTHORAX; HEMOPERITONEUM; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; KIDNEY PANCREAS TRANSPLANTATION; LIPID METABOLISM; METABOLIC REGULATION; NAUSEA; PANCREAS ISLET TRANSPLANTATION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VEIN THROMBOSIS; VOMITING;

C-PEPTIDE; DIABETES MELLITUS; HUMANS; ISLETS OF LANGERHANS TRANSPLANTATION;

EID: 35648982927     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2007.07.004     Document Type: Review

References (77)

1. DCCT. The Diabetes Control and Complications Trial Research Group. The effect of intensive. treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
2. Bloomgarden Z.T. Diabetes complications. Diabetes Care 27 6 (2004) 1506-1514
3. Bloomgarden Z.T. Glycemic treatment: control of glycemia. Diabetes Care 27 5 (2004) 1227-1234
4. Bailes B.K. Diabetes mellitus and its chronic complications. Aorn J 76 2 (2002) 266-276 278-282 [quiz: 283-6]
5. Ricordi C. Islet transplantation: a brave new world. Diabetes 52 7 (2003) 1595-1603
6. Lacy P.E., and Kostianovsky M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 16 1 (1967) 35-39
7. Ballinger W.F., and Lacy P.E. Transplantation of intact pancreatic islets in rats. Surgery 72 2 (1972) 175-186
8. Sutherland D.E., Matas A.J., Goetz F.C., et al. Transplantation of dispersed pancreatic islet tissue in humans: autografts and allografts. Diabetes 29 Suppl 1 (1980) 31-44
9. Ricordi C., Lacy P.E., Finke E.H., et al. Automated method for isolation of human pancreatic islets. Diabetes 37 4 (1988) 413-420
10. Lake S.P., Bassett P.D., Larkins A., et al. Large-scale purification of human islets utilizing discontinuous albumin gradient on IBM 2991 cell separator. Diabetes 38 Suppl 1 (1989) 143-145
11. Lake S.P., Chamberlain J., Bassett P.D., et al. Successful reversal of diabetes in nude rats by transplantation of isolated adult human islets of Langerhans. Diabetes 38 2 (1989) 244-248
12. Tzakis A.G., Ricordi C., Alejandro R., et al. Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet 336 8712 (1990) 402-405
13. Ricordi C., Tzakis A.G., Carroll P.B., et al. Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation 53 2 (1992) 407-414
14. Hering B.J., Browatzki C.C., Schultz A.O., et al. Islet Transplant Registry report on adult and fetal islet allografts. Transplant Proc 26 2 (1994) 565-568
15. Hering B.J., Browatzki C.C., Schultz A., et al. Clinical islet transplantation-registry report, accomplishments in the past and future research needs. Cell Transplant 2 4 (1993) 269-282 [discussion: 283-305]
16. Luzi L., Hering B.J., Socci C., et al. Metabolic effects of successful intraportal islet transplantation in insulin-dependent diabetes mellitus. J Clin Invest 97 11 (1996) 2611-2618
17. Shapiro A.M., Lakey J.R., Ryan E.A., et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343 4 (2000) 230-238
18. Fiorina P., Folli F., Zerbini G., et al. Islet transplantation is associated with improvement of renal function among uremic patients with type 1 diabetes mellitus and kidney transplants. J Am Soc Nephrol 14 8 (2003) 2150-2158
19. Shapiro A.M., Ricordi C., Hering B.J., et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 355 13 (2006) 1318-1330
20. Fiorina P., Folli F., Bertuzzi F., et al. Long-term beneficial effect of islet transplantation on diabetic macro-/microangiopathy in type 1 diabetic kidney-transplanted patients. Diabetes Care 26 4 (2003) 1129-1136
21. Davalli A.M., Maffi P., Socci C., et al. Insights from a successful case of intrahepatic islet transplantation into a type 1 diabetic patient. J Clin Endocrinol Metab 85 10 (2000) 3847-3852
22. Alejandro R., Angelico M.C., Ricordi C., et al. Long-term function of islet allograft in type 1 diabetes mellitus. Transplant Proc 27 6 (1995) 3158
23. Luzi L., Perseghin G., Brendel M.D., et al. Metabolic effects of restoring partial beta cell function after islet allotransplantation in type 1 diabetic patients. Diabetes 50 2 (2001) 277-282
24. Leahy J.L., Bonner-Weir S., and Weir G.C. Abnormal glucose regulation of insulin secretion in models of reduced B cell mass. Diabetes 33 7 (1984) 667-673
25. Mattsson G., Jansson L., Nordin A., et al. Evidence of functional impairment of syngenetically transplanted mouse pancreatic islets retrieved from the liver. Diabetes 53 4 (2004) 948-954
26. Jindal R.M., Sidner R.A., and Milgrom M.L. Post-transplant diabetes mellitus. The role of immunosuppression. Drug Saf 16 4 (1997) 242-257
27. Filler G., Neuschulz I., Vollmer I., et al. Tacrolimus reversibly reduces insulin secretion in paediatric renal transplant recipients. Nephrol Dial Transplant 15 6 (2000) 867-871
28. Montori V.M., Basu A., Erwin P.J., et al. Post-transplantation diabetes: a systematic review of the literature. Diabetes Care 25 3 (2002) 583-592
29. Fabian M.C., Lakey J.R., Rajotte R.V., et al. The efficacy and toxicity of rapamycin in murine islet transplantation. In vitro and in vivo studies. Transplantation 56 5 (1993) 1137-1142
30. Bell E., Cao X., Moibi J.A., et al. Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets. Diabetes 52 11 (2003) 2731-2739
31. Shapiro A.M., Gallant H., Hao E., et al. Portal vein immunosuppressant levels and islet graft toxicity. Transplant Proc 30 2 (1998) 641
32. Desai N.M., Goss J.A., Deng S., et al. Elevated portal vein drug levels of sirolimus and tacrolimus in islet transplant recipients: local immunosuppression or islet toxicity?. Transplantation 76 11 (2003) 1623-1625
33. Luzi L. Metabolic strategies to predict and improve intrahepatic islet graft function. J Mol Med 77 1 (1999) 49-56
34. Rickels M.R., Schutta M.H., Markmann J.F., et al. β cell function following human islet transplantation for type 1 diabetes. Diabetes 54 1 (2005) 100-106
35. Rickels M.R., Schutta M.H., Mueller R., et al. Islet cell hormonal responses to hypoglycemia after human islet transplantation for type 1 diabetes. Diabetes 54 11 (2005) 3205-3211
36. Gupta V., Wahoff D.C., Rooney D.P., et al. The defective glucagon response from transplanted intrahepatic pancreatic islets during hypoglycemia is transplantation site-determined. Diabetes 46 1 (1997) 28-33
37. Kendall D.M., Rooney D.P., Smets Y.F., et al. Pancreas transplantation restores epinephrine response and symptom recognition during hypoglycemia in patients with long-standing type 1 diabetes and autonomic neuropathy. Diabetes 46 2 (1997) 249-257
38. Kendall D.M., Teuscher A.U., and Robertson R.P. Defective glucagon secretion during sustained hypoglycemia following successful islet allo- and autotransplantation in humans. Diabetes 46 1 (1997) 23-27
39. Paty B.W., Ryan E.A., Shapiro A.M., et al. Intrahepatic islet transplantation in type 1 diabetic patients does not restore hypoglycemic hormonal counter-regulation or symptom recognition after insulin independence. Diabetes 51 12 (2002) 3428-3434
40. Meyer C., Hering B.J., Grossmann R., et al. Improved glucose counter-regulation and autonomic symptoms after intraportal islet transplants alone in patients with long-standing type 1 diabetes mellitus. Transplantation 66 2 (1998) 233-240
41. Cryer P.E., Davis S.N., and Shamoon H. Hypoglycemia in diabetes. Diabetes Care 26 6 (2003) 1902-1912
42. Ryan E.A., Shandro T., Green K., et al. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes 53 4 (2004) 955-962
43. Rickels M.R., Naji A., and Teff K.L. Insulin sensitivity, glucose effectiveness, and free fatty acid dynamics after human islet transplantation for type 1 diabetes. J Clin Endocrinol Metab 91 6 (2006) 2138-2144
44. Senior P.A., Paty B.W., Cockfield S.M., et al. Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. Am J Transplant 5 9 (2005) 2318-2323
45. Fiorina P., Venturini M., Folli F., et al. Natural history of kidney graft survival, hypertrophy, and vascular function in end-stage renal disease type 1 diabetic kidney-transplanted patients: beneficial impact of pancreas and successful islet cotransplantation. Diabetes Care 28 6 (2005) 1303-1310
46. Digon III B.J., Rother K.I., Hirshberg B., et al. Sirolimus-induced interstitial pneumonitis in an islet transplant recipient. Diabetes Care 26 11 (2003) 3191
47. Hirshberg B., Rother K.I., Digon III B.J., et al. Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression: the National Institutes of Health experience. Diabetes Care 26 12 (2003) 3288-3295
48. Zhang N., Su D., Qu S., et al. Sirolimus is associated with reduced islet engraftment and impaired beta-cell function. Diabetes 55 9 (2006) 2429-2436
49. Makhlouf L., Kishimoto K., Smith R.N., et al. The role of autoimmunity in islet allograft destruction: major histocompatibility complex class II matching is necessary for autoimmune destruction of allogeneic islet transplants after T cell costimulatory blockade. Diabetes 51 11 (2002) 3202-3210
50. Venturini M., Angeli E., Maffi P., et al. Technique, complications, and therapeutic efficacy of percutaneous transplantation of human pancreatic islet cells in type 1 diabetes: the role of US. Radiology 234 2 (2005) 617-624
51. Markmann J.F., Rosen M., Siegelman E.S., et al. Magnetic resonance-defined periportal steatosis following intraportal islet transplantation: a functional footprint of islet graft survival?. Diabetes 52 7 (2003) 1591-1594
52. Maffi P., Angeli E., Bertuzzi F., et al. Minimal focal steatosis of liver after islet transplantation in humans: a long-term study. Cell Transplant 14 10 (2005) 727-733
53. Maffi P.B.F., De Taddeo F., Magistretti P., et al. Kidney function after islet transplant alone in type 1 diabetes: impact of immunosuppressive therapy on progression of diabetic nephropathy. Diabetes Care 30 5 (2007) 1150-1155
54. Robertson R.P. Islet transplantation as a treatment for diabetes-a work in progress. N Engl J Med 350 7 (2004) 694-705
55. Ryan E.A., Paty B.W., Senior P.A., et al. Five-year follow-up after clinical islet transplantation. Diabetes 54 7 (2005) 2060-2069
56. Davalli A.M., Ogawa Y., Scaglia L., et al. Function, mass, and replication of porcine and rat islets transplanted into diabetic nude mice. Diabetes 44 1 (1995) 104-111
57. Han D., Leith J., Alejandro R., et al. Peripheral blood cytotoxic lymphocyte gene transcript levels differ in patients with long-term type 1 diabetes compared to normal controls. Cell Transplant 14 6 (2005) 403-409
58. Fiorina P., Folli F., Maffi P., et al. Islet transplantation improves vascular diabetic complications in patients with diabetes who underwent kidney transplantation: a comparison between kidney-pancreas and kidney-alone transplantation. Transplantation 75 8 (2003) 1296-1301
59. Fiorina P., Gremizzi C., Maffi P., et al. Islet transplantation is associated with an improvement of cardiovascular function in type 1 diabetic kidney transplant patients. Diabetes Care 28 6 (2005) 1358-1365
60. Forst T., De La Tour D.D., Kunt T., et al. Effects of proinsulin C peptide on nitric oxide, microvascular blood flow, and erythrocyte Na+,K+-ATPase activity in diabetes mellitus type I. Clin Sci (Lond) 98 3 (2000) 283-290
61. Johansson B.L., Borg K., Fernqvist-Forbes E., et al. Beneficial effects of C peptide on incipient nephropathy and neuropathy in patients with type 1 diabetes mellitus. Diabet Med 17 3 (2000) 181-189
62. Jonasson P., Nygren P.A., Jornvall H., et al. Integrated bioprocess for production of human proinsulin C peptide via heat release of an intracellular heptameric fusion protein. J Biotechnol 76 2-3 (2000) 215-226
63. Wahren J., Ekberg K., Johansson J., et al. Role of C peptide in human physiology. Am J Physiol Endocrinol Metab 278 5 (2000) E759-E768
64. Cotter M.A., Ekberg K., Wahren J., et al. Effects of proinsulin C peptide in experimental diabetic neuropathy: vascular actions and modulation by nitric oxide synthase inhibition. Diabetes 52 7 (2003) 1812-1817
65. Johansson B.L., Sundell J., Ekberg K., et al. C peptide improves adenosine-induced myocardial vasodilation in type 1 diabetes patients. Am J Physiol Endocrinol Metab 286 1 (2004) E14-E19
66. Johansson B.L., Wahren J., and Pernow J. C peptide increases forearm blood flow in patients with type 1 diabetes via a nitric oxide-dependent mechanism. Am J Physiol Endocrinol Metab 285 4 (2003) E864-E870
67. Rigler R., Pramanik A., Jonasson P., et al. Specific binding of proinsulin C peptide to human cell membranes. Proc Natl Acad Sci USA 96 23 (1999) 13318-13323
68. Forst T., Kunt T., Pfutzner A., et al. New aspects on biological activity of C peptide in IDDM patients. Exp Clin Endocrinol Diabetes 106 4 (1998) 270-276
69. Forst T., Kunt T., Pohlmann T., et al. Biological activity of C peptide on the skin microcirculation in patients with insulin-dependent diabetes mellitus. J Clin Invest 101 10 (1998) 2036-2041
70. Forst T., Pfutzner A., Kunt T., et al. Skin microcirculation in patients with type 1 diabetes with and without neuropathy after neurovascular stimulation. Clin Sci (Lond) 94 3 (1998) 255-261
71. Kunt T., Schneider S., Pfutzner A., et al. The effect of human proinsulin C peptide on erythrocyte deformability in patients with type 1 diabetes mellitus. Diabetologia 42 4 (1999) 465-471
72. Kitamura T., Kimura K., Jung B.D., et al. Proinsulin C peptide rapidly stimulates mitogen-activated protein kinases in Swiss 3T3 fibroblasts: requirement of protein kinase C, phosphoinositide 3-kinase, and pertussis toxin-sensitive G-protein. Biochem J 355 Pt 1 (2001) 123-129
73. Kitamura T., Kimura K., Jung B.D., et al. Proinsulin C-peptide activates cAMP response element-binding proteins through the p38 mitogen-activated protein kinase pathway in mouse lung capillary endothelial cells. Biochem J 366 Pt 3 (2002) 737-744
74. Ido Y., Vindigni A., Chang K., et al. Prevention of vascular and neural dysfunction in diabetic rats by C peptide. Science 277 5325 (1997) 563-566
75. Ricordi C., and Strom T.B. Clinical islet transplantation: advances and immunological challenges. Nat Rev Immunol 4 4 (2004) 259-268
76. Calafiore R., Basta G., Luca G., et al. Microencapsulated pancreatic islet allografts into nonimmunosuppressed patients with type 1 diabetes: first two cases. Diabetes Care 29 1 (2006) 137-138
77. Secchi A., Taglietti M.V., Socci C., et al. Insulin secretory patterns and blood glucose homeostasis after islet allotransplantation in IDDM patients: comparison with segmental- or whole-pancreas transplanted patients through a long-term longitudinal study. J Mol Med 77 1 (1999) 133-139